FORMULATION AND EVALUATION OF DOCETAXEL TRIHYDRATE LOADED SELF-ASSEMBLED NANOCARRIERS FOR TREATMENT OF HER2 POSITIVE BREAST CANCER
Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer tend to be more aggressive among all breast cancers. Breast cancers withÂ HER2 gene amplification or HER2 protein overexpression are called HER2-positive. It tends to grow faster and are more likely to spread and come back compared to HER2-negative breast cancers. HER2 positive breast cancer is often treated with chemotherapy drugs called anthracylines (e.g. doxorubicine, epirubicine), taxanes (e.g. Docetaxel, peclitaxel) as well as some others, usually in combination of two or more chemotherapy drugs1 but the development of potential drug delivery system by using nanotechnology is also the important aspect for the proper treatment of HER2 positive breast cancer. The aim of this study was to develop DTX-loaded self assembled nanocarriers (SANs) for treatment of HER2 positive breast cancer and also to evaluate their efficacy to release the drug by controlled manner. SANs were prepared from a glyceryl monooleate, PluronicÂ® F127 (0.5 â€“ 1.5 % w/v) and PluronicÂ® F68 (0.25-1.0 %w/v) in different concentration with or without docetaxel trihydrate (DTX) (2.0%w/v) by high pressure homogenization, before preparation compatibility of drug and polymers was studied by differential scanning calorimetry (DSC) and FTIR spectroscopy. Prepared SANs was then subject to different evaluation test particle size, zeta potential, % entrapment efficiency, drug content, in vitro drug release study, measurement of pH, and stability study. Particle size of SANs prepared with PluronicÂ® F127 was found in the range of 170 nm to 280 nm whereas SANs with PluronicÂ® F68 was found between 200 to 240 nm and it shows more negative zeta potential value than -30 mV. More than 90 % of DTX was found to be entrapped in SANs formulations loaded with DTX 2.0% w/v. Drug released study revealed that formulation F9 containing 0.25% PF68 shows 89.59 % release after 12 h and F5containing 1.0% PF127 releases 96.56% drug after 12 h. Results of one month stability study shows that the SANs formulations were found to be stable over a one month. Hence, the DTX-loaded SANs was act as an potential drug carrier to fulfill the demand of cancer therapeutics.
2. Rizwan SB, Boyd BJ, Rades T, Hook S, Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins, Expert Opinion on Drug Delivery, 2010; 7(10):1133-1144
3. Bei D, Marszalek J, Youan BC, Formulation of Dacarbazine Loaded Cubosomesâ€”Part I: Influence of Formulation Variables, AAPS Pharm Sci Tech. 2009; 10(3):1032-1039.
4. Fontell, K., Mandell, L., and Ekwall, P., "Isotropic Mesophases in Systems Containing Amphiphilic Compounds," Acta Chem. Scand. 1968; 22:3209-23.
5. Shah JC, Sadhale Y, Chilukuri DM, Cubic phase gels as drug delivery systems, Adv Drug Deliver Rev. 2001; 47:229â€“250.
6. Burrows R, Collett JH, Attwood D, The release of drugs from monoglyceride-water liquid crystalline phases, Int. J. Pharm. 1994; 111:283-293.
7. Drummond CJ, Fong C, Surfactant self assembly objects as novel drug delivery vehicles, Current Openion Colloid Interface Science (2000) 449-456.
8. Barauskas J, Johnsson M, Joabsson F, Tiberg F. Cubic phase nanoparticles (cubosome): principles for controlling size, structure, and stability. Langmuir 2005; 21(6):2569â€“77.
9. Barauskas J, Johnsson M, Tiberg F. Self-assembled lipid superstructures: beyond vesicles and liposomes. Nano Lett. 2000; 5(8):1615â€“19.
10. Rarokar NR, Saoji SD, Raut NA, Taksande JB, Khedekar PB, Dave VS. Nanostructured Cubosomes in a Thermoresponsive Depot System: An Alternative Approach for the Controlled Delivery of Docetaxel. AAPS PharmSciTech. 2015; 17:436-445.
11. Fong W, Hanley T, Boyd B, Stimuli responsive liquid crystals provide â€˜on-demandâ€™ drug delivery in vitro and in vivo, J. Control. Release. 2009; 135:218-226.
12. Dong YD, Larson I, Hanley T, Boyd BJ, Bulk and dispersed aqueous phase behaviour of phytantriol: effect of vitamin E acetate and F127 polymer on liquid crystal nanostructure, Langmuir, 2006; 22:9512-9518.
13. Luzzati V, Tardieu A, Gulik-Kryzwicki T, Rivas E, Riess-Husson F, Nature (London) 1968; 220:485-487.
14. Gaikwad V, et al. Formulation and evaluation of In-Situ gel of metoprolol tartrate for nasal delivery. J Pharm Res. 2010; 3:788-793.
15. Maghsoudi A, Shojaosadati SA, Vasheghani Farahani E. 5hFluorouracil-loaded BSA nanoparticles: formulation optimization and in-vitro release study. AAPS Pharm Sci Tech. 2008; 9(4):1092â€“6.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).